<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7577013\results\search\country\results.xml">
  <result pre="Perspectives: Perspectives Meeting Report: PMDA Public Workshop on Pharmacometrics at" exact="Japan" post="Public Workshop on Pharmacometrics at Japan Kijima et al."/>
  <result pre="Workshop on Pharmacometrics at Japan Public Workshop on Pharmacometrics at" exact="Japan" post="Kijima et al. KijimaShinichi1kijima-shinichi@pmda.go.jpOchiaiYoshinori1IshiguroAkihiro1[1], Pharmaceuticals and Medical Devices AgencyTokyoJapan"/>
  <result pre="properly cited and is not used for commercial purposes.file:PSP4-9-550.pdf Funding" exact="Japan" post="Agency for Medical Research and Development 10.13039/100006190 JP16mk0101003JP19mk0101090 fig-count:"/>
  <result pre="analysis and physiologicallyâ€�based pharmacokinetic modelâ€™s analysis, which was held in" exact="Japan" post="in July 2019. Recent drug developments have paid attention"/>
  <result pre="the current situation of M&amp;amp;S utilization in drug developments in" exact="Japan" post="have led to increased needs to develop new guidelines"/>
  <result pre="to facilitate appropriate application of M&amp;amp;S for regulatory purpose. The" exact="Japan" post="Agency for Medical Research and Development (AMED) funded research"/>
  <result pre="abroad. In the first session, Atsunori Kaibara, PhD, Eli Lilly" exact="Japan" post="K.K., presented the impacts of ER analysis on approval"/>
  <result pre="by foreignâ€�affiliated company. The speaker concluded that M&amp;amp;S utilizations in" exact="Japan" post="are expected to be facilitated by the implementation of"/>
  <result pre="ER analysis guideline in preparation. Akiyuki Suzuki, MSc, Pfizer R&amp;amp;D" exact="Japan" post="G.K., presented a development project of Revatio for treatment"/>
  <result pre="current situation of PBPK model analysis for regulatory purpose in" exact="Japan" post="and offered an overview of progress on development of"/>
  <result pre="authority because the underutilization of M&amp;amp;S by domestic companies in" exact="Japan" post="was pointed out by the industry speaker in session"/>
  <result pre="authorities, including the US Food and Drug Administration in the" exact="United States" post="and the European Medicines Agency that have provided guidances"/>
  <result pre="to promote appropriate utilization of M&amp;amp;S for regulatory purpose in" exact="Japan" post="but also to serve as an agenda for future"/>
  <result pre="Funding This research was supported by research grants from the" exact="Japan" post="Agency for Medical Research and Development (AMED; JP16mk0101003 and"/>
 </snippets>
</snippetsTree>
